Compositions of peptide inhibitors of Interleukin-23 receptor
The present invention relates to compositions of peptide inhibitors of the interleukin-23 receptor (IL-23R) or pharmaceutically acceptable salt or solvate forms thereof, corresponding pharmaceutical compositions, methods and/or uses for treatment of autoimmune inflammation and related diseases and disorders.
1. A pharmaceutical composition comprising:
a peptide of SEQ ID NO: 1 or a pharmaceutically acceptable salt or solvate form thereof in an amount of from about 0.1% to about 15% (w/w) of the pharmaceutical composition; and
one or more pharmaceutically acceptable excipients.
2. The pharmaceutical composition of claim 1 , wherein the peptide of SEQ ID NO: 1 or a pharmaceutically acceptable salt or solvate form thereof, has the chemical structure:
and wherein the peptide of SEQ ID NO: 1 or a pharmaceutically acceptable salt or solvate form thereof is a pharmaceutically acceptable salt form.
3. The pharmaceutical composition of claim 1 , wherein the peptide of SEQ ID NO: 1 or a pharmaceutically acceptable salt or solvate form thereof is an acetate form.
4. The pharmaceutical composition of claim 3 , wherein the acetate form is in an amorphous form.
5. The pharmaceutical composition of claim 1 , wherein the amount of the peptide of SEQ ID NO: 1 or a pharmaceutically acceptable salt or solvate form thereof is from about 1 mg to about 1000 mg.
6. The pharmaceutical composition of claim 1 , wherein the amount of the peptide of SEQ ID NO: 1 or a pharmaceutically acceptable salt or solvate form thereof is from about 10 mg to about 300 mg.
7. The pharmaceutical composition of claim 1 , wherein the amount of the peptide of SEQ ID NO: 1 or a pharmaceutically acceptable salt or solvate form thereof is from about 25 mg to about 150 mg.
8. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition further comprises an absorption enhancer.
9. The pharmaceutical composition of claim 8 comprising:
a peptide of SEQ ID NO: 1 or a pharmaceutically acceptable salt or solvate form thereof in an amount of from about 0.1% to about 15% (w/w) of the pharmaceutical composition;
an absorption enhancer in an amount from about 10% to about 60% (w/w); and
one or more pharmaceutically acceptable excipients.
10. A method of treating an inflammatory disease in a subject comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition of claim 1 .
11. A pharmaceutical composition comprising:
a peptide of SEQ ID NO: 1 or a pharmaceutically acceptable salt or solvate form thereof in an amount of from about 0.1% to about 20% (w/w) of the pharmaceutical composition; and
one or more pharmaceutically acceptable excipients.
12. The pharmaceutical composition of claim 11 , wherein the peptide of SEQ ID NO: 1 or a pharmaceutically acceptable salt or solvate form thereof, has the chemical structure:
and wherein the peptide of SEQ ID NO: 1 or a pharmaceutically acceptable salt or solvate form thereof is a pharmaceutically acceptable salt form.
13. The pharmaceutical composition of claim 12 , wherein the amount of the peptide of SEQ ID NO: 1 or a pharmaceutically acceptable salt or solvate form thereof is from about 1 mg to about 1000 mg.
14. The pharmaceutical composition of claim 13 , wherein the amount of the peptide of SEQ ID NO: 1 or a pharmaceutically acceptable salt or solvate form thereof is from about 10 mg to about 500 mg.
15. The pharmaceutical composition of claim 14 , wherein the amount of the peptide of SEQ ID NO: 1 or a pharmaceutically acceptable salt or solvate form thereof is from about 10 mg to about 300 mg.
16. A method of treating an inflammatory disease in a subject comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition of claim 11 .